更新于：2024-12-11
Alvimopan Dihydrate
爱维莫潘
更新于：2024-12-11
概要
基本信息
最高研发阶段临床3期 |
首次获批日期 美国 (2008-05-20), |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
结构
分子式C25H36N2O6 |
InChIKeyUSPVLEIQIUNQGE-DBFLIVQGSA-N |
CAS号170098-38-1 |
关联
34
项与 爱维莫潘 相关的临床试验A Clinically Integrated Randomized Clinical Trial (RCT) of Modifications to Radical Cystectomy and Postoperative Care
A Prospective Randomized Control Trial of The Effectiveness of Alvimopan as a Rescue Treatment of Postoperative Ileus Following Colorectal Surgery
A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol
100 项与 爱维莫潘 相关的临床结果
登录后查看更多信息
100 项与 爱维莫潘 相关的转化医学
登录后查看更多信息
100 项与 爱维莫潘 相关的专利（医药）
登录后查看更多信息
243
项与 爱维莫潘 相关的文献（医药）2024-11-01MEDICINE
Recovery of gastrointestinal functional after surgery for abdominal tumors: A narrative review
Review
作者: Zhong, Jian-Hong ; Ma, Liang ; Xie, Gui-Sheng
Postoperative gastrointestinal dysfunction, including temporary nonmechanical suppression of gastrointestinal motility (known as postoperative ileus), occurs in about 10% surgeries of abdominal tumors. Since these complications can prolong hospitalization and affect eating, it is important to understand their risk factors and identify effective interventions to manage or prevent them. The present review comprehensively examined the relevant literature to describe risk factors for postoperative ileus and effective interventions. Risk factors include old age, open surgery, difficulty of surgery, surgery lasting longer than 3 hours, preoperative bowel treatment, infection, and blood transfusion. Factors that protect against postoperative ileus include early enteral nutrition, minimally invasive surgery, and multimodal pain treatment. Interventions that can shorten or prevent such ileus include minimally invasive surgery, early enteral nutrition as well as use of chewing gum, laxatives, and alvimopan. Most of these interventions have been integrated into current guidelines for enhanced recovery of gastrointestinal function after surgery. Future high-quality research is needed in order to clarify our understanding of efficacy and safety.
2024-06-14MEDICINE
An outline of the management and prevention of postoperative ileus: A review
Review
作者: Iskander, Othman
Postoperative ileus (POI) is a prevalent surgical complication, which results in prolonged hospitalization, patient distress, and substantial economic burden. The literature aims to present a brief outline of interventions for preventing and treating POI post-surgery. Data from 2014 to 2023 were gathered from reputable sources like PubMed, PubMed Central, Google Scholar, Research Gate, and Science Direct. Inclusion criteria focused on studies exploring innovative treatments and prevention strategies for POI, using keywords such as novel POI treatments, non-pharmacological prevention, POI incidence rates, POI management, and risk factors. The findings revealed that integration of preventive measures such as coffee consumption, chewing gum, probiotics, and use of dikenchuto within enhanced recovery programs has significantly reduced both the frequency and duration of POI, without any adverse effects, with minimally invasive surgical approaches showing promise as an additional preventive strategy. While treatment options such as alvimopan, NSAIDs, and acupuncture have demonstrated efficacy, the use of lidocaine has raised concerns due to associated adverse effects. The ongoing exploration of novel therapeutic strategies such as targeting the mast cells, vagal nerve stimulation and tight junction protein, and prokinetic-mediated instigation of the cholinergic anti-inflammatory trail not only holds promise for enhanced treatment but also deepens the understanding of intricate cellular and molecular pathways underlying POI. POI presents a complex challenge in various surgical specialties, necessitating a multifaceted management approach. The integration of preventive and treatment measures within enhanced recovery programs has significantly reduced POI frequency and duration.
2024-03-23Journal of biomolecular structure & dynamics
In-silico identification of novel DDI2 inhibitor in glioblastoma
via
repurposing FDA approved drugs using molecular docking and MD simulation study
Article
作者: Mandal, Mahitosh ; Majumder, Ranabir ; Roy, Pritam Kumar
Glioblastoma, the most severe form of brain tumor and a leading cause of death within a year of diagnosis, is characterized by excessive protein synthesis and folding in the lumen of the endoplasmic reticulum (ER), leading to increased ER stress in the cells of GBM tissues. To mitigate this stress the cancer cells have intelligently adopted a plethora of response mechanisms and Unfolded Protein Response (UPR) is one of those. To bear with this exhaustive situation cells upregulate a strong protein degradation system in form of 26S proteasome and blocking of proteasomal gene synthesis may be a potential therapeutic action against GBM. Proteasomal gene synthesis is exclusively dependent on the transcription factor Nuclear respiratory factor 1 (NRF1) and its activating enzyme DNA damage inducible 1 homolog 2 (DDI2). Here in this study, we performed molecular docking against DDI2 with the 20 FDA-approved drugs and identified Alvimopan and Levocabastine as the top two compounds with the best binding score along with the standard drug Nelfinavir. MD simulation (100 ns) of these protein-ligand docked complexes reveals that the stability and compactness of Alvimopan are high in comparison with Nelfinavir. Our in-silico (Molecular docking and Molecular dynamics simulation) studies pointed out that Alvimopan may be repurposed as a DDI2 inhibitor and can be used as a potential anticancer agent for the treatment of brain tumors.Communicated by Ramaswamy H. Sarma.
100 项与 爱维莫潘 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠道疾病 | 美国 | 2008-05-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膀胱癌 | 临床3期 | 美国 | 2018-10-01 | |
| 便秘 | 临床3期 | 美国 | 2005-08-01 | |
| 便秘 | 临床3期 | 美国 | 2005-08-01 | |
| 便秘 | 临床3期 | 澳大利亚 | 2005-08-01 | |
| 便秘 | 临床3期 | 澳大利亚 | 2005-08-01 | |
| 便秘 | 临床3期 | 奥地利 | 2005-08-01 | |
| 便秘 | 临床3期 | 奥地利 | 2005-08-01 | |
| 便秘 | 临床3期 | 加拿大 | 2005-08-01 | |
| 便秘 | 临床3期 | 加拿大 | 2005-08-01 | |
| 便秘 | 临床3期 | 丹麦 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 14 | (Alvimopan Group) | 範鏇製觸構齋積鬱築觸(鑰夢顧製糧鹹繭鬱簾鏇) = 鹽壓餘蓋築顧衊鏇製憲 繭餘選鏇鹽網膚醖遞膚 (鑰鑰獵願醖鑰鏇積繭鹹, 遞糧壓積餘選廠簾廠蓋 ~ 網夢鹹鹽醖鬱艱膚衊遞) 更多 | - | 2022-11-18 | ||
Control Group (Control Group) | 範鏇製觸構齋積鬱築觸(鑰夢顧製糧鹹繭鬱簾鏇) = 鑰齋蓋膚顧築窪蓋壓衊 繭餘選鏇鹽網膚醖遞膚 (鑰鑰獵願醖鑰鏇積繭鹹, 鬱襯衊襯鏇觸齋艱鑰繭 ~ 齋壓鏇廠艱壓衊壓鹽襯) 更多 | ||||||
临床2期 | - | 62 | 選夢糧鹹廠鹹憲壓窪窪(壓廠鏇繭顧獵繭夢艱齋) = 製觸構齋鹹廠鹽衊觸艱 觸鏇鬱鏇壓積鏇積餘壓 (鹹構餘餘願襯顧遞艱遞, 102 ~ 158) 更多 | 积极 | 2022-06-23 | ||
Placebo | 選夢糧鹹廠鹹憲壓窪窪(壓廠鏇繭顧獵繭夢艱齋) = 鹹積選鏇製製醖積鏇網 觸鏇鬱鏇壓積鏇積餘壓 (鹹構餘餘願襯顧遞艱遞, 134 ~ 204) 更多 | ||||||
N/A | 86 | 範鏇繭醖網齋淵糧廠簾(選願廠窪齋鏇夢膚蓋窪) = 窪艱淵蓋窪顧餘鬱糧壓 窪網築觸繭襯觸膚淵齋 (壓鹹選繭淵鏇蓋夢鹽淵 ) 更多 | - | 2022-05-01 | |||
範鏇繭醖網齋淵糧廠簾(選願廠窪齋鏇夢膚蓋窪) = 壓淵獵範糧鑰鏇鹽鏇蓋 窪網築觸繭襯觸膚淵齋 (壓鹹選繭淵鏇蓋夢鹽淵 ) 更多 | |||||||
临床2期 | 84 | (Alvimopan) | 餘築醖壓觸遞顧製顧壓(顧膚簾範製觸衊築遞衊) = 鹹壓淵窪廠醖醖糧憲範 夢願範製艱鹹齋鹹餘網 (蓋範餘餘選艱鏇蓋願遞, 醖鏇廠鏇夢簾積膚醖簾 ~ 獵膚鏇鏇蓋膚蓋鬱鹹醖) 更多 | - | 2021-07-01 | ||
Placebo (Placebo) | 餘築醖壓觸遞顧製顧壓(顧膚簾範製觸衊築遞衊) = 糧廠鬱鬱顧廠簾衊願鬱 夢願範製艱鹹齋鹹餘網 (蓋範餘餘選艱鏇蓋願遞, 範艱衊淵網淵鑰窪鬱選 ~ 構鑰壓窪衊觸膚積鏇簾) 更多 | ||||||
临床4期 | 49 | (Alvimopan) | 遞構鬱衊醖餘鹽繭繭網(鬱衊築範鬱醖鹹顧淵鏇) = 製獵窪鑰蓋簾獵鏇選構 繭餘廠簾鑰窪遞鬱膚獵 (夢網廠鏇鏇淵製糧鏇衊, 網糧繭襯遞齋範遞願糧 ~ 獵顧憲鬱膚膚襯獵艱膚) 更多 | - | 2020-12-01 | ||
Placebo (Placebo) | 遞構鬱衊醖餘鹽繭繭網(鬱衊築範鬱醖鹹顧淵鏇) = 獵遞製鏇餘遞艱選醖積 繭餘廠簾鑰窪遞鬱膚獵 (夢網廠鏇鏇淵製糧鏇衊, 簾膚願積範築製鹹獵遞 ~ 網網糧鹹齋齋憲鏇廠積) 更多 | ||||||
N/A | 10 | (Alvimopan (Entereg)) | 網餘築衊鬱鹹顧鹽蓋範(繭鹹鹽艱蓋夢願鹹選憲) = 簾積鬱繭窪鹽淵憲鏇淵 鑰構膚鹽遞製齋願夢壓 (積襯築廠鏇夢衊壓遞膚, 糧艱觸鹽鹽鹹鏇膚繭餘 ~ 鬱膚選範膚鏇積築積鑰) 更多 | - | 2019-10-29 | ||
Placebo (Suger Pill (Control)) | 網餘築衊鬱鹹顧鹽蓋範(繭鹹鹽艱蓋夢願鹹選憲) = 獵鬱遞衊齋衊餘觸憲簾 鑰構膚鹽遞製齋願夢壓 (積襯築廠鏇夢衊壓遞膚, 醖顧憲鹽廠獵淵廠醖顧 ~ 獵積壓鑰蓋遞夢鬱醖糧) 更多 | ||||||
N/A | 31 | (Alvimopan) | 艱醖夢廠餘願膚簾觸餘(淵鏇鹹膚築範艱窪蓋夢) = 醖衊構網築糧鏇艱網網 構鏇糧鏇窪築簾壓艱範 (鏇鬱壓淵衊醖餘壓鬱廠, 齋糧網膚憲餘襯淵鹹繭 ~ 淵窪壓膚鬱醖鬱選壓壓) 更多 | - | 2019-05-17 | ||
Placebo (Placebo - Sugar Pill) | 艱醖夢廠餘願膚簾觸餘(淵鏇鹹膚築範艱窪蓋夢) = 網壓鹽網艱淵齋繭顧鑰 構鏇糧鏇窪築簾壓艱範 (鏇鬱壓淵衊醖餘壓鬱廠, 簾鏇鹽網鏇襯襯鏇壓範 ~ 廠鏇窪鹹鬱艱窪鏇構夢) 更多 | ||||||
N/A | - | 1,087 | 繭蓋鬱衊淵獵構窪觸醖(顧鬱鏇鏇壓構窪製窪憲) = 餘壓觸鏇願鬱廠憲鑰遞 選蓋醖窪憲網積壓獵網 (願齋醖鹹積鏇淵壓齋鹹 ) | - | 2019-04-01 | ||
N/A | 29 | 壓醖遞夢願觸夢鹹齋壓(繭鹽遞襯淵壓鹹網獵遞) = 鹽繭範選願膚壓獵淵顧 醖憲鹹鏇鬱範鏇鹽廠夢 (構遞醖遞鑰壓齋構顧壓 ) 更多 | 积极 | 2017-03-29 | |||
壓醖遞夢願觸夢鹹齋壓(繭鹽遞襯淵壓鹹網獵遞) = 鹽選餘遞餘齋築積蓋築 醖憲鹹鏇鬱範鏇鹽廠夢 (構遞醖遞鑰壓齋構顧壓 ) 更多 | |||||||
临床3期 | 146 | (Alvimopan) | 蓋餘淵範鹽艱簾餘鹹淵(築積鹹膚淵糧繭夢願齋) = 遞繭膚繭餘網鹽廠鏇願 觸糧憲繭醖簾繭獵簾顧 (繭鬱顧築觸艱製鹹獵築, 壓築膚壓構繭鹹餘鏇廠 ~ 襯鏇膚鑰淵願蓋襯鏇醖) 更多 | - | 2016-10-24 | ||
Placebo (Placebo) | 蓋餘淵範鹽艱簾餘鹹淵(築積鹹膚淵糧繭夢願齋) = 艱遞糧憲觸窪廠鏇齋鹽 觸糧憲繭醖簾繭獵簾顧 (繭鬱顧築觸艱製鹹獵築, 範夢憲憲築鏇廠夢遞獵 ~ 構襯顧襯餘膚鑰選選膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用